AbbVie began 2025 with a T cell engager deal in China, and it’s ending the year with another one.
The Chicago-area pharmaceutical giant is going to Zelgen Biopharmaceuticals for a clinical-stage T cell engager called …
Read More from Endpoints News
AbbVie does T cell engager deal in China for Zelgen’s DLL3-targeted drug
